---
layout: default
title: Pralatrexate
description: "Pralatrexate çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 136
evidence_level: L4
indication_count: 10
---

# Pralatrexate

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pralatrexateï¼šå¾å‘¨é‚ŠTç´°èƒæ·‹å·´ç˜¤åˆ°èƒ¸è†œä¸Šçš®å‹é–“çš®ç˜¤

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Pralatrexate å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Pralatrexate åŸæœ¬ç”¨æ–¼æ²»ç™‚å¾©ç™¼æˆ–é ‘å›ºå‹å‘¨é‚ŠTç´°èƒæ·‹å·´ç˜¤ (PTCL)ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**èƒ¸è†œä¸Šçš®å‹é–“çš®ç˜¤ (pleural epithelioid mesothelioma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **1 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ²»ç™‚å¾©ç™¼æˆ–é ‘å›ºå‹å‘¨é‚ŠTç´°èƒæ·‹å·´ç˜¤(PTCL)ã€‚é©æ‡‰ç—‡ä¾æ“šç‚ºè…«ç˜¤åæ‡‰ç‡ï¼Œç›®å‰æ²’æœ‰è³‡æ–™è­‰å¯¦ç„¡æƒ¡åŒ–å­˜æ´»æœŸæˆ–æ•´é«”å­˜æ´»æœŸæ”¹å–„ç­‰è‡¨åºŠæ•ˆç›Š |
| é æ¸¬æ–°é©æ‡‰ç—‡ | pleural adenomatoid tumorã€relapsing-remitting multiple sclerosisã€pleural biphasic mesotheliomaã€pleural epithelioid mesotheliomaã€lymphohistiocytoid mesotheliomaã€pericardium cancerã€pleural sarcomatoid mesotheliomaã€malignant peritoneal mesotheliomaã€well differentiated papillary mesotheliomaã€pleural mesothelioma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.89% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Research Question |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. pleural adenomatoid tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒPralatrexate æ˜¯ä¸€ç¨®æŠ—è‘‰é…¸ä»£è¬çš„è—¥ç‰©ï¼Œ</p>
<p>å…¶æˆåˆ†åœ¨å¾©ç™¼æˆ–é ‘å›ºå‹å‘¨é‚ŠTç´°èƒæ·‹å·´ç˜¤ (PTCL) ä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼èƒ¸è†œä¸Šçš®å‹é–“çš®ç˜¤ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. relapsing-remitting multiple sclerosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pleural biphasic mesothelioma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pleural epithelioid mesothelioma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17409804/" target="_blank">17409804</a></td><td>2007</td><td>Article</td><td>Journal of thoracic oncology :</td><td>Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patien...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. lymphohistiocytoid mesothelioma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. pericardium cancer</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. pleural sarcomatoid mesothelioma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. malignant peritoneal mesothelioma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. well differentiated papillary mesothelioma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. pleural mesothelioma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17409804/" target="_blank">17409804</a></td><td>2007</td><td>Article</td><td>Journal of thoracic oncology :</td><td>Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11595715/" target="_blank">11595715</a></td><td>2001</td><td>Article</td><td>Clinical cancer research : an </td><td>Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21301589/" target="_blank">21301589</a></td><td>2010</td><td>Article</td><td>Cancer management and research</td><td>Cancer chemotherapy: targeting folic acid synthesis.</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026419è™Ÿ | æœç˜¤åœæ³¨å°„åŠ‘ | æ³¨å°„åŠ‘ | æ²»ç™‚å¾©ç™¼æˆ–é ‘å›ºå‹å‘¨é‚ŠTç´°èƒæ·‹å·´ç˜¤(PTCL)ã€‚é©æ‡‰ç—‡ä¾æ“šç‚ºè…«ç˜¤åæ‡‰ç‡ï¼Œç›®å‰æ²’æœ‰è³‡æ–™è­‰å¯¦ç„¡æƒ¡åŒ–å­˜æ´»æœŸæˆ–æ•´é«”å­˜æ´»æœŸæ”¹å–„ç­‰è‡¨åºŠæ•ˆç›Š |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰© |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä¸­åº¦ |
| è‡´åæ€§åˆ†ç´š | ä¸­åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚è…åŠŸèƒ½ |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šPralatrexate èˆ‡ Deferiprone å’Œ Samarium (153Sm) lexidronam æœ‰ä¸»è¦äº¤äº’ä½œç”¨ï¼Œéœ€æ³¨æ„ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Liver Failure** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè‚æ¯’æ€§ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šResearch Question**

**ç†ç”±ï¼š**
é›–ç„¶ç›®å‰åªæœ‰ä¸€ç¯‡ Phase II æ–‡ç»æ”¯æŒ Pralatrexate ç”¨æ–¼èƒ¸è†œä¸Šçš®å‹é–“çš®ç˜¤çš„æ½›åœ¨ç™‚æ•ˆï¼Œä½†å…¶æŠ—è‘‰é…¸ä»£è¬çš„æ©Ÿè½‰å¯èƒ½é©ç”¨æ–¼æ­¤é¡è…«ç˜¤ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä»¥ç¢ºèªå…¶åœ¨èƒ¸è†œä¸Šçš®å‹é–“çš®ç˜¤ä¸­çš„ç™‚æ•ˆ
- æ›´è©³ç´°çš„è—¥ç‰©ä½œç”¨æ©Ÿè½‰è³‡æ–™ï¼ˆMOAï¼‰

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Tetryzoline]({{ "/drugs/tetryzoline/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Salicylamide]({{ "/drugs/salicylamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Brodalumab]({{ "/drugs/brodalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Riluzole]({{ "/drugs/riluzole/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Dl-Alpha-Tocopherol]({{ "/drugs/dl-alpha-tocopherol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Pralatrexateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/pralatrexate/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_pralatrexate,
  title = {Pralatrexateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pralatrexate/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
